



ASX Release

Letter to PTXO Option Holders

Melbourne, Australia (31 May 2018): Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) advises that the following letter has been despatched to PTXO option holders in accordance with ASX Listing Rule 6.24 and that the letter provides notice that the expiry date of those options is 30 June 2018.

If you require more information on how to exercise your options, please contact Automic Pty Ltd on 1300 288 664 (Australia) or +61 2 9698 5414 (international). If you are unsure whether to take up your options, please contact your stockbroker, financial advisor or other professional advisor.

ENDS

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing targeted therapies that address specific mutations that drive cancer and contribute to resistance.

Prescient's lead drug candidate **PTX-200** inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This promising compound is now the focus of three current clinical trials:

- Phase 2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and Florida's H. Lee Moffitt Cancer Center (Moffitt). PTX-200 showed encouraging efficacy signals in the Phase 1b study.
- Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapsed and refractory Acute Myeloid Leukemia, being conducted the Moffitt; Yale Cancer Center in New Haven, Connecticut (Yale) and Kansas University Medical Center (KUMC) under the leadership of Professor Jeffrey Lancet, MD.
- Phase 1b/2 trial of PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

Prescient's second novel drug candidate, **PTX-100**, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It inhibits the activation of Rho, Rac and Ral circuits in cancer cells, which act as key oncogenic pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase 1 trial in advanced solid tumors and will be the focus of studies in Ras and RhoA mutant malignancies, namely RhoA mutant lymphomas.



Further enquiries:

Melanie Leydin
Company Secretary
Prescient Therapeutics Limited
+61 3 9692 7222

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited ("Prescient" or the "Company"), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words 'estimate', 'project', 'intend', 'expect', 'plan', 'believe', 'guidance', and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management's current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words "believes," "plans," "expects," "anticipates," and words of similar import, constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favorable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.



31 May 2018

Dear Option Holder,

EXPIRY OF LISTED OPTIONS

You are the registered holder of options (the **Options**) in Prescient Therapeutics Limited (ASX: PTX) (**Prescient** or the **Company**). These options were issued to shareholders who participated in applying for shares through the Company's June 2016 Placement, Rights Issue and Shortfall placement in July 2016 or have been acquired on market since that time.

The Options will expire at 5:00pm on Saturday 30 June 2018.

Option Holders Choices:

1. Exercise all or a portion of your options

You may complete the enclosed 'Notice of Exercise of Options' form in full, sign it and send it to Automic Pty Limited by post. Exercise of options will be completed and processed in accordance with the Terms of Options set out on the back of the Application Form. Payment must be made by Cheque, payable to Prescient Therapeutics Limited. Alternatively, you can pay by BPAY using the details on the form.

2. Sell all or a portion of your options

The Options are listed (ASX: PTXO) and may be traded on the ASX. The last traded price for PTXO options was \$0.001 on 29 May 2018. Your options will cease trading at close of trade on Monday 25 June 2018 (last day of quotation).

3. Do Nothing

If you choose to do nothing, your Options will expire at **5:00pm (AEST) Saturday 30 June 2018** and have no value.

Additional Information required by the ASX Listing Rules

In accordance with the ASX Listing Rules, the Company advises the following:

- (a) The name of the option holder is contained on the enclosed personalised 'Notice of Exercise of Options' form.
- (b) The number of Options held, and the number of fully paid ordinary shares in the Company to be issued on the conversion of the Options is contained in the enclosed personalised 'Notice of Exercise of Options' for the option holder.
- (c) The exercise price for the Options is \$0.18 per option.
- (d) The due date for payment of the exercise price is on or before **5:00pm (AEST) Saturday 30 June 2018**.
- (e) If payment is not received by 5:00pm (AEST) on Saturday 30 June 2018, then your Options will expire with no value and no further entitlement will exist.
- (f) Official quotation of Options on the ASX will cease at the close of trading on Monday 25 June 2018.
- (g) The last traded price for Prescient shares was \$0.125 on 30 May 2018.

- (h) The highest and lowest market price for Prescient shares during the 3 months immediately before the notice is as follows:

Highest: \$0.18 (18 cents) on 10 April 2018
Lowest: \$0.061 (6.1 cents) on 4 March 2018

- (i) The board confirms that there is no underwriting agreement in place for the exercise of the Options.

Further Information

The board encourages you to consider your choices as an Option holder and to take the action that best suits your individual circumstances. If you require more information on how to exercise your Options, please contact Automic Pty Limited on 1300 288 664 (Australia) or +61 2 9698 5414 (international). If you are unsure whether to take up your Options, please contact your stockbroker, financial advisor or other professional advisor.

Yours faithfully,

PRESCIENT THERAPEUTICS LIMITED

A handwritten signature in blue ink, appearing to read "Melanie Leydin", is written over a faint, light blue grid background.

Melanie Leydin
Company Secretary



Prescient Therapeutics Limited | ACN 006 569 106

All Registry Communication to:



PO Box 2226, Strawberry Hills NSW 2012
1300 288 664 (within Australia)
+61 2 9698 5414 (international)
hello@automic.com.au
www.automic.com.au

[EntityRegistrationDetailsLine1Envelope]
[EntityRegistrationDetailsLine2Envelope]
[EntityRegistrationDetailsLine3Envelope]
[EntityRegistrationDetailsLine4Envelope]
[EntityRegistrationDetailsLine5Envelope]
[EntityRegistrationDetailsLine6Envelope]

SRN/HIN: [HolderNumber]
Security Code: PTXO
Number of Options held: [PTXOHolding]
Option Expiry Date: 30/06/2018
Exercise Price: \$0.18

[ReplaceNoImages]

NOTICE OF EXERCISE OF OPTIONS

I/we hereby exercise the following number of options and make payment in Australian currency for the amount payable. Please allot me/us Ordinary Shares calculated on the basis of one Ordinary Share for every one Option which I/we exercise.

I/We agree to accept such Shares subject to the Constitution of Prescient Therapeutics Limited.

1. Number of Options Exercised (Enter all or part of PTXO options)
Total payment required (multiply box 1 by \$0.18 per option)
A\$

2. Payment: You can pay either by BPAY or cheque
Option A - BPAY
Biller Code:
Ref: [BPayCRN]
Telephone & Internet Banking - BPAY
Contact your bank or financial institution to make this payment from your cheque, savings, debit, credit card or transaction account. More info: www.bpay.com.au

Option B - Cheque
• Make your cheque payable to "Prescient Therapeutics Limited"
• Return your cheque together with this signed and completed 'Notice of Exercise of Options'

3. Contact details
Telephone Number
Contact Name (PLEASE PRINT)
Email Address
SUPPORT YOUR COMPANYY: By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible).

4. Please sign below and return the form to Automic
Securityholder 1
Securityholder 2
Securityholder 3
Submitting your 'Notice of Exercise of Options':
Please return the completed and signed form together with your cheque payment or a copy of your funds transfer receipt to Automic to the address provided at the top of this form.

PTXO option terms

Exercise of New Options	Each Option is exercisable immediately on issue. The Options may be exercised at any time before their expiry date, wholly or in part, by delivering a duly completed form of notice of exercise together with a cheque for the exercise price. Prescient will issue one Share for each New Option exercised.
Terms of Shares issued	Any Shares issued as a result of exercising a New Option will be issued on the same terms and rank in all respects on equal terms, with existing Shares.
Quotation of Shares issued	Application for official quotation of Shares allotted and issued as a result of the exercise of the New Options will be made within three Business Days from the date of issue of the Shares.
Expiration of New Options	Each New Option will have an expiration date that is 30 June 2018.
Exercise price of New Options	\$0.18 upon exercise to acquire each Share.
Option register	New Options will be registered in the name of a Shareholder in an option register maintained by the share registry. The share registry will issue holding statements that evidence the number of New Options held by the Shareholder. No option certificates will be issued.
Reconstruction of capital	If there is a reconstruction (including consolidation, sub-division, reduction or return) of the issued capital of Prescient: (a) the number of New Options or the exercise price of the New Options or both will be adjusted as specified in Listing Rule 7.22 as it applies at the time of the reorganisation; and (b) in all other respects the terms for the exercise of the New Options will remain unchanged.
Adjustment where pro rata issue of Shares, bonus shares or stock dividends	If there is a pro rata issue of Shares, the exercise price of the New Options may be adjusted as specified in Listing Rule 6.22.2. If there is a bonus or cash issue of Shares, the number of Shares issued upon exercise of the New Options will be adjusted as specified in Listing Rule 6.22.3.
Notice of adjustments	Prescient will give written notice to the New Option holder of any adjustment of the exercise price of the New Options and any increase or decrease in the number of New Options.
Dividend rights	While they remain unexercised, the New Options will not give a holder an entitlement to receive any dividends declared and paid by Prescient for Shares.
Applicable law	Each New Option is issued subject to: (a) the Corporations Act; (b) the Listing Rules; and (c) the Company's constitution.